Takeshita A, Shinjo K, Naito K, Ohnishi K, Sugimoto Y, Yamakawa Y, Tanimoto M, Kitamura K, Naoe T, Ohno R
Division of Haematology, Department of Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Br J Haematol. 2000 Jan;108(1):90-2. doi: 10.1046/j.1365-2141.2000.01823.x.
We analysed the relationship between all-trans retinoic acid (ATRA) resistance and P-glycoprotein (P-gp)-associated multidrug resistance (MDR) in acute promyelocytic leukaemia (APL). There was no difference in the intracellular ATRA accumulation between NB4 cells and an MDR1 cDNA-transduced NB4 subline and between ATRA-resistant NB4 cells (NB4/RA) and an MDR1 cDNA-transduced NB4/RA subline. PSC833, a MDR modifier, did not increase the intracellular accumulation of ATRA or affect the expression of CD11b, the nitroblue tetrazolium (NBT) reduction activity, the proportion of apoptotic cells or the morphology of these four ATRA-treated cell lines. Similar results were obtained in the analysis of APL cells from five patients relapsed after ATRA-induced complete remission.
我们分析了急性早幼粒细胞白血病(APL)中全反式维甲酸(ATRA)耐药与P-糖蛋白(P-gp)相关的多药耐药(MDR)之间的关系。NB4细胞与转导了MDR1 cDNA的NB4亚系之间,以及ATRA耐药的NB4细胞(NB4/RA)与转导了MDR1 cDNA的NB4/RA亚系之间,细胞内ATRA蓄积没有差异。MDR调节剂PSC833并未增加ATRA的细胞内蓄积,也未影响这四种经ATRA处理的细胞系的CD11b表达、硝基蓝四氮唑(NBT)还原活性、凋亡细胞比例或形态。对5例经ATRA诱导完全缓解后复发的患者的APL细胞进行分析,也得到了类似结果。